PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN CHILDREN WITH CHRONIC RENAL-DISEASE - A PROSPECTIVE-STUDY OF ANTIBODY-RESPONSE AND DURATION

We studied the antibody response to pneumococcal serotypes 3 and 14 af ter pneumococcal polysaccharide vaccine was administered to 41 childre n with renal disease, One month after vaccination, 76% and 61% of pati ents achieved at least a twofold titer rise to serotypes 3 and 14, res pectively; this finding was comparable to historic control values, One year after vaccination, the majority of patients retained protective antibody levels, Achieving a titer greater than or equal to 1.0 mu g/m l IgG at 1 month was highly predictive of retaining a protective antib ody level greater than or equal to 0.15 mu g/ml at 1 year.